Assessment of metabolic stability and pharmacokinetics by LC–MS/MS and establishment of the safe dose of IMID‐2, a novel anticancer molecule under drug discovery
Biomedical Chromatography · 2023
DOI: 10.1002/bmc.5618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2023. Verfasst von S Pranush Kumar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Pyruvate kinase (PK) M2 activators ramp up glycolysis in cancer cells, leading to a reversal of the Warburg effect in cancer cells. A promising PKM2 activator molecule, IMID‐2, developed by the National Institute of Pharmaceutical Education and Research—Ahmedabad showed promising anticancer activity against MCF‐7 and COLO‐205 cell lines, which represent breast and colon cancer. Its physicochemical properties, like solubility, ionization constant, partition coefficient and distribution constant, have already been established. Its metabolic pathway is also well established through in vitro and in vivo metabolite profiling and reported previously. In this study, we have evaluated the metabolic stability of IMID‐2 using LC–MS/MS and investigated the safety aspect of the molecule through an acute oral toxicity study. In vivo studies in rats confirmed that the molecule is safe even at a dose level of 175 mg/kg. Furthermore, a pharmacokinetic study of IMID‐2 was also carried out using LC–MS/MS to understand its absorption, distribution, metabolism, and excretion profile. The molecule was found to have promising bioavailability through the oral route. This research work is thus another step in the drug testing of this promising anticancer molecule. The molecule can be considered to be a potential anticancer lead based on the earlier report substantiated by current findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India.
- Department of Physiology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic.
ORCID-Profile: Pinaki Sengupta
Zitieren
APA
Kumar, S. P., Jadav, T., Sahu, A. K., Ghosh Chowdhary, M., Siwach, A., Patel, H., Patel, S., Rajput, N., Shard, A., Khairnar, A., & Sengupta, P. (2023). Assessment of metabolic stability and pharmacokinetics by LC–MS/MS and establishment of the safe dose of IMID‐2, a novel anticancer molecule under drug discovery. Biomedical Chromatography. https://doi.org/10.1002/bmc.5618
Vancouver
Kumar SP, Jadav T, Sahu AK, Ghosh Chowdhary M, Siwach A, Patel H, et al. Assessment of metabolic stability and pharmacokinetics by LC–MS/MS and establishment of the safe dose of IMID‐2, a novel anticancer molecule under drug discovery. Biomedical Chromatography. 2023. doi:10.1002/bmc.5618
BibTeX
@article{Kumar2023,
author = {Kumar, S Pranush and Jadav, Tarang and Sahu, Amit Kumar and Ghosh Chowdhary, Moumita and Siwach, Ankit and Patel, Harit and Patel, Sagarkumar and Rajput, Niraj and Shard, Amit and Khairnar, Amit and Sengupta, Pinaki},
title = {Assessment of metabolic stability and pharmacokinetics by LC–MS/MS and establishment of the safe dose of IMID‐2, a novel anticancer molecule under drug discovery},
journal = {Biomedical Chromatography},
year = {2023},
doi = {10.1002/bmc.5618}
}
EUVIMED